{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"description":"Progression-free survival is defined as the time from protocol therapy initiation to the disease progression or death from any cause, censored at date last known progression free for those who have not progressed or died","groups":[{"description":"* Cycles 1-9\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n  * Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle\n* Cycle 10-24\n\n  * Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle\n  * Lenalidomide is administered orally on days 1-21 on a 28 days cycle\n* Supportive measures consistent with optimal patient care may be given throughout the study\n\nIxazomib: Oral, proteasome inhibitor\n\nLenalidomide: Oral, immunomodulatory agent\n\nDexamethasone: Oral, steroid","id":"OG000","title":"Ixazomib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Time from protocol therapy initiation to the disease progression or death from any cause, censored at date last known progression free for those who have not progressed or died, or up to 60 months post initiation of therapy","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Participants"}